tiprankstipranks
Lucid SOS esophageal cell collection device subject to Class II FDA recall
PremiumThe FlyLucid SOS esophageal cell collection device subject to Class II FDA recall
2M ago
Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale
PremiumCompany Announcements
Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale
2M ago
Lucid Diagnostics Highlights Promising EsoGuard Study Results
PremiumCompany Announcements
Lucid Diagnostics Highlights Promising EsoGuard Study Results
2M ago
LUCD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsLUCD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Lucid Diagnostics announces data from clinical validation study of EsoGuardPAVmed
PremiumThe Fly
Lucid Diagnostics announces data from clinical validation study of EsoGuardPAVmed
3M ago
Lucid Diagnostics initiated with a Buy at Maxim
PremiumThe Fly
Lucid Diagnostics initiated with a Buy at Maxim
4M ago
Lucid Diagnostics price target lowered to $2.50 from $3 at BTIG
PremiumThe FlyLucid Diagnostics price target lowered to $2.50 from $3 at BTIG
8M ago
Lucid Diagnostics expands executive team
PremiumThe Fly
Lucid Diagnostics expands executive team
8M ago
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
PremiumPress Releases
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100